Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428834 | 0.95 | L3MBTL1 (0.33) | L3MBTL1SLC5A2KDM4EUSP2LMNA | |
| SCHEMBL6307307 | 0.90 | L3MBTL1 (0.38) | L3MBTL1SLC5A2KDM4EUSP2LMNA | |
| SCHEMBL6258332 | 0.90 | MAPT (0.31) | KDM4EUSP2LMNAGAAMAPT | |
| SCHEMBL6254058 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL6317949 | 0.86 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL6313922 | 0.86 | MAPT (0.33) | SLC5A2KDM4EUSP2LMNAGAA | |
| SCHEMBL6306456 | 0.85 | FDPS (0.34) | SLC5A2KDM4EUSP2LMNAGAA | |
| SCHEMBL6253453 | 0.83 | FDPS (0.36) | SLC5A2KDM4EUSP2LMNAGAA | |
| SCHEMBL6306546 | 0.82 | TAS1R3 (0.34) | L3MBTL1 | |
| SCHEMBL6313748 | 0.81 | SMN1; SMN2 (0.33) | L3MBTL1LMNAGAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | L3MBTL1 2787/4885SLC5A2 497/4885KDM4E 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.